-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 AMbv2/9XSvVO49TiOXZR3SRuV6l76kOZJ8d04gS5DLUKZxTM+mz1c3WrA/sAP3sC
 27yc2pztceH2zoKO7gSVgw==

<SEC-DOCUMENT>0000950134-07-019892.txt : 20070912
<SEC-HEADER>0000950134-07-019892.hdr.sgml : 20070912
<ACCEPTANCE-DATETIME>20070912165859
ACCESSION NUMBER:		0000950134-07-019892
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070906
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070912
DATE AS OF CHANGE:		20070912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IRIDEX CORP
		CENTRAL INDEX KEY:			0001006045
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				770210467
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1230

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-27598
		FILM NUMBER:		071113725

	BUSINESS ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
		BUSINESS PHONE:		6509404700

	MAIL ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f33744e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, DC 20549</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B><DIV align="center"><DIV style="font-size: 3pt; margin-top: 12pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 6pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of<BR>
The Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported)</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>September&nbsp;6, 2007</B></DIV>

<DIV align="center" style="font-size: 12pt"><B><DIV align="center"><DIV style="font-size: 3pt; margin-top: 12pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>


<DIV align="center" style="font-size: 24pt; margin-top: 8pt"><B>IRIDEX CORPORATION</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>0-27598</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>77-0210467</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of <BR>
incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>1212 Terra Bella Avenue<BR>
Mountain View, California 94043</B><BR>
(Address of principal executive offices, including zip code)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(650)&nbsp;940-4700</B><BR>
(Registrant&#146;s telephone number, including area code)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">(Former name or former address, if changed since last report)</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">Item&nbsp;9.01. Financial Statements and Exhibits</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">EXHIBIT INDEX</A></TD></TR>
<TR><TD colspan="9"><A HREF="f33744exv99w1.htm">EXHIBIT 99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>






<!-- link1 "Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers" -->
<DIV align="left"><A NAME="000"></A></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On September&nbsp;6, 2007, director Robert K. Anderson resigned from the board of directors (the &#147;Board
of Directors&#148;) of IRIDEX Corporation, (the &#147;Company&#148;) and from the Compensation and Nominating
Committee thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On September&nbsp;6, 2007, William M. Moore was appointed to the Company&#146;s Board of Directors, pursuant
to provisions of that certain Securities Purchase Agreement (the &#147;Agreement&#148;), dated August&nbsp;31,
2007, by and between the Company and the purchasers named therein (the &#147;Purchasers&#148; or &#147;BlueLine&#148;).
Pursuant to the Agreement the Company sold $5&nbsp;million of
securities in the Company. In addition, BlueLine received the right to designate two individuals for
appointment to the Company&#146;s Board of Directors, one of which is at BlueLine&#146;s discretion and the
second of which is subject to the Company&#146;s reasonable approval. Furthermore, subject to the
fiduciary duties of the Board of Directors, for so long as BlueLine
holds any shares of Series&nbsp;A Preferred
Stock issued pursuant to the Agreement, the Company will continue to nominate such designees for
reelection at each of the Company&#146;s annual or special meetings at which election of directors to
the Board of Directors is proposed for consideration by the
stockholders. Mr.&nbsp;Moore, director at BlueLine Partners LLC, is the discretionary designee of BlueLine under the
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In connection with Mr.&nbsp;Moore&#146;s election to the Board of Directors, the Company also approved the
grant of a non-qualified stock option for the purchase of 15,000&nbsp;shares of common stock which
grant will be effective as of September&nbsp;31, 2007 at an exercise price per share equal to the fair
market value on that date. Assuming continued service on the Board of Directors, such options vest
and become exercisable over 36&nbsp;months, with 1/36<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> of the shares subject to the option
vesting each month thereafter. In addition, Mr.&nbsp;Moore will automatically receive a nonstatutory
option to purchase 5,000&nbsp;shares of common stock upon his annual reelection to the Board of
Directors by the stockholders, with 1/12<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> of the shares vesting each month. The
options granted to Mr.&nbsp;Moore will be granted under the Company&#146;s 1998 Stock Plan and have a term of
7&nbsp;years unless terminated sooner upon the termination of Mr.&nbsp;Moore&#146;s status as a director or
otherwise pursuant to the 1998 Stock Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Moore currently serves on the board of directors of Natus Medical Inc. a company he co-founded
in 1990 and for which he served as its CEO until 1993. He has served
as a director
of Blue Line Partners, a private equity firm, since February&nbsp;2004, and currently serves on the
board of directors of Criticare Systems, Inc. From March&nbsp;2003 until February&nbsp;2004, Mr.&nbsp;More was a
general partner of Alpine Partners, a venture capital firm. Mr.&nbsp;Moore served as CEO of Metasensors,
Inc., a medical device company, from 1998 to March&nbsp;2003. Mr.&nbsp;Moore holds a Bachelor of
Science degree in Business from the University of Utah.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A copy of the press release announcing Mr.&nbsp;Anderson&#146;s resignation and Mr.&nbsp;Moore&#146;s appointment is
attached hereto as Exhibit&nbsp;99.1 and is incorporated herein by reference.
</DIV>

<!-- link1 "Item&nbsp;9.01. Financial Statements and Exhibits" -->
<DIV align="left"><A NAME="001"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Exhibits</U>.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="93%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left">Exhibit</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Number</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Description</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release dated September&nbsp;12, 2007.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="002"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>

<TD colspan="3" align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <B>IRIDEX CORPORATION</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ <FONT style="font-variant: SMALL-CAPS">Barry G. Caldwell</FONT>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left"><B>Barry G. Caldwell</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left"><B>President and Chief Executive Officer</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Date: September&nbsp;12, 2007
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 "EXHIBIT INDEX" -->
<DIV align="left"><A NAME="003"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT INDEX</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="93%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left">Exhibit</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Number</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Description</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release dated September&nbsp;12, 2007.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f33744exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>FOR IMMEDIATE RELEASE</B><BR>
Contact:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Larry Tannenbaum<BR>
Chief Business Officer<BR>
650-940-4700</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">September&nbsp;12, 2007<BR>
Mountain View, California

</DIV>

<DIV align="center" style="font-size: 12pt; margin-top: 18pt">WILLIAM MOORE APPOINTED TO IRIDEX BOARD OF DIRECTORS
</DIV>

<DIV align="center" style="font-size: 10pt"><I>Moore is Director at BlueLine Partners, Recent Equity Investors in IRIDEX</I></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IRIDEX Corporation (Nasdaq: IRIX) announced today the appointment of William M. Moore to its
Board of Directors. Mr.&nbsp;Moore, a director at BlueLine Partners, replaces Robert K. Anderson who
has left the Board of Directors for personal reasons. IRIDEX recently completed a private
placement of equity with BlueLine and as part of the financing BlueLine has the right to designate
an individual for appointment to the IRIDEX Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;Will is a great addition to our Board as he brings 25&nbsp;years of experience leading medical
device businesses,&#148; said Theodore A. Boutacoff, Chairman of the Board at IRIDEX. &#147;Will&#146;s
financial, marketing and overall management expertise will be key assets to IRIDEX as we continue
to grow the Company. We are delighted with Will&#146;s appointment and look forward to working with him
on our shared goal of enhancing shareholder value. At the same time, on behalf of the entire
Board, I would like to thank Bob Anderson for his eight years of service as an IRIDEX Director. We
will miss his wisdom, wit and contributions.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Will Moore currently serves on the Board of Directors of Criticare Systems and
Natus Medical Inc. (Nasdaq: BABY) a company he co-founded in 1990 and for which he served as its
CEO until 1993. Mr.&nbsp;Moore was a co-founder and, from 1998 until 2003, CEO of MetaSENSORS Inc. a
health care development company. From 1993 to 1995, Mr.&nbsp;Moore was the Vice President of Marketing
and Sales and a member of the Board of Directors of Arzco Medical Systems Inc. He negotiated the
acquisition of the company from the Marmon Group and later the sale of the assets to Baxter
Healthcare Inc. In addition, from 1993 to 1998, Mr.&nbsp;Moore served on the Board of Directors of
Responsive Medical Applications Inc. and negotiated the sale of the company to HillRom Inc. From
1983 to 1988, Mr.&nbsp;Moore was the Director of Marketing for Nellcor Inc., now a division of TYCO Inc.
during which time sales grew from zero to over $100,000,000. Mr.&nbsp;Moore earned his B.S. degree from
the University of Utah.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;I am excited about joining the Board of Directors at IRIDEX,&#148; said Mr.&nbsp;Moore. &#147;IRIDEX has
earned a reputation of developing laser products that are clinically effective, reliable, portable,
versatile and affordable, and its acquisition of the Laserscope aesthetic business has helped
diversify the Company&#146;s portfolio. With BlueLine&#146;s recent infusion of capital, I believe the
Company is well on its way to recovering from the challenges of the Laserscope transaction. IRIDEX
is continuing to implement other cost-saving strategies to realize synergies between the
ophthalmology and new aesthetics businesses, and I am confident that the results of our efforts
will help bring a return to profitability.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About IRIDEX</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IRIDEX Corporation is a leading worldwide provider of therapeutic based laser systems,
disposable laser probes and delivery devices to treat eye diseases in ophthalmology and skin
disorders in the aesthetics market. IRIDEX products are sold in the United States through a direct
sales force and internationally through a combination of a direct sales force and a network of
approximately 97 independent distributors into 107 countries. For further information, visit the
Company&#146;s website at www.iridex.com.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Safe Harbor Statement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This announcement contains forward-looking statements within the meaning of Section&nbsp;27A of the
Securities Act of 1933, as amended and Section&nbsp;21E of the Securities Act of 1934, as amended,
relating to the company&#146;s use of the proceeds of the financing, growth in the company&#146;s revenues,
the company&#146;s future growth, its ability to successfully integrate the aesthetics business
acquired from Laserscope and to realize projected synergies between the ophthalmology and new
aesthetics businesses, and its ability to return to profitability. Actual results could differ
materially and adversely from those projected in the forward-looking statements based on, among
other things, the company&#146;s ability to effectively integrate the aesthetics business acquired from
Laserscope and to realize efficiencies and synergies relating thereto, and the results of the
company&#146;s ongoing business, including order and shipment rates for the company&#146;s ophthalmology and
dermatology product lines, the rate of sales to OEM customers, the rate of growth in sales of
disposables and services, the rate of introduction and market acceptance of the company&#146;s products,
and the impact of any continuing weakness and uncertainties related to general economic conditions
or weakness in overall demand in the company&#146;s markets, especially with regard to the company&#146;s
dermatology products which are typically used for elective procedures that can be deferred. Please
see a detailed description of these risks and other risks that the company is subject to contained
in our Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for the fiscal year ended
December&nbsp;30, 2006 filed with the Securities and Exchange Commission. Forward- looking statements
contained in this announcement are made as of this date and will not be updated.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
